Picard Medical, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
Picard Medical reports Q1 2026 revenue growth alongside significant liquidity challenges and a going concern warning.
AMEX
Picard Medical, Inc. reported increased revenue and a significant cash infusion from its recent IPO, but continued to post substantial net losses for the nine months ended September 30, 2025.
AMEX
Picard Medical, Inc. completed its Initial Public Offering, raising $17 million in gross proceeds, despite reporting a significant increase in net loss and ongoing operational challenges for the first half of 2025.